MSMotoaki Saito

Motoaki Saito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Motoaki Saito has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Keisuke Satoh

    Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishi-machi, Yonago, 683-8503 Tottori, Japan

    12 shared publications
  • Ikuo Miyagawa

    Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago

    11 shared publications
  • Yukako Kinoshita

    Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishi-machi, Yonago, 683-8503 Tottori, Japan

    10 shared publications
  • Itaru Satoh

    Division of Molecular Pharmacology, Tottori University Faculty of Medicine, 86 Nishi-machi, Yonago, 683-8503 Tottori, Japan

    7 shared publications
  • Hiroto Suzuki

    5 shared publications
  • Masashi Yamada

    5 shared publications

Latest Publications

  • Characterization of the ileal muscarinic receptor system in 70-week-old type II Goto–Kakizaki diabetic rats; effects of cyclohexenonic long-chain fatty alcohol

    by Shin-Ichi Okada, Motoaki Saito, Yukako Kinoshita, Itaru Satoh, Emi Kazuyama, Atsushi Hayashi, Keisuke Satoh, Susumu Kanzaki


  • Pharmacological Properties, Functional Alterations and Gene Expression of Muscarinic Receptors in Young and Old Type 2 Goto-Kakizaki Diabetic Rat Bladders

    by Motoaki Saito, Shin-Ichi Okada, Emi Kazuyama, Itaru Satoh, Yukako Kinoshita, Keisuke Satoh

    We investigated pharmacological properties, functional alterations and gene expression of the muscarinic receptor system in young and old Goto-Kakizaki rat bladders. Male 12 and 70-week-old Goto-Kakizaki rats and age matched male Wistar rats were used in this study. Bladder function was estimated by voiding behavior, cystometric and functional studies using KCl, carbachol and various concentrations of subtype selective muscarinic antagonists, ie pirenzepine, methoctramine, 4-DAMP (Sigma) and atropine (Wako Pure Chemical Industries, Osaka, Japan). The participation levels of M(2) and M(3) receptor mRNA in the bladder were investigated by real-time polymerase chain reaction. In voiding behavior studies there were no significant differences in urine output, although an age related decrease in micturition frequency and an age related increase in single voided volume were observed in Goto-Kakizaki and Wistar rats. In cystometric studies there were no significant differences in maximum detrusor pressure or bladder capacity, although residual urine volume was significantly increased in 70-week-old Goto-Kakizaki rats. In functional studies carbachol induced detrusor contractility was significantly increased in Goto-Kakizaki rats in each age group. Estimated pA(2) values for atropine, pirenzepine, methoctramine and 4-DAMP (Sigma) indicated that the carbachol induced contractile response was mediated through the M(3) receptor subtype in all groups. Furthermore, muscarinic M(2) and M(3) receptor mRNA was significantly up regulated in 70-week-old Goto-Kakizaki rat bladders. Our data indicate that noninsulin dependent diabetes induces alterations in the muscarinic receptor system, which may contribute to the development of diabetic cystopathy.


  • Effects of N-hexacosanol on nitric oxide synthase system in diabetic rat nephropathy

    by Shinichi Okada, Motoaki Saito, Emi Kazuyama, Takuya Hanada, Yasuo Kawaba, Atsushi Hayashi, Keisuke Satoh, Susumu Kanzaki

    We attempted to clarify the effects of cyclohexenonic long-chain fatty alcohol (N-hexacosanol) on nitric oxide synthase (NOS) in streptozotocin-induced diabetic nephropathy. After induction of experimental diabetes with streptozotocin, rats were maintained for 8 weeks with or without treatment by N-hexacosanol (8 mg/kg i.p. every day). Urinary albumin excretion, blood chemistry, immunoblot analysis, and real-time polymerase chain reactions (real-time PCR) of endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS) were investigated. Although N-hexacosanol had no effects on serum glucose or insulin level, it normalized serum creatinine and urinary albumin excretion. N-hexacosanol was found to improve the diabetes-induced alterations in the eNOS, iNOS, and nNOS protein and their mRNA levels. Histologically, N-hexacosanol inhibited the progression to glomerular sclerosis. Our data suggest that N-hexacosanol improves diabetes-induced NOS alterations in the kidney, resulting in the amelioration of diabetic nephropathy.


  • Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia–reperfusion injury in the rat bladder

    by Tomoharu Kono, Shin-Ichi Okada, Motoaki Saito

    In the present study, we evaluated the effect of neutrophil elastase inhibitor, sivelestat sodium hydrate on ischemia–reperfusion injury in the rat bladder. Rat abdominal aorta was clamping with a small clip to induce ischemia–reperfusion injury in the bladder. Eight-week-old male Sprague Dawley rats were divided into four groups; sham-operated control rats, 30 min ischemia–60 min reperfusion (IR) rats, and IR rats treated with 15 or 60 mg/kg of sivelestat sodium hydrate. Sixty minutes prior to induction of ischemia, sivelestat sodium hydrate was administrated intraperitoneally. Real-time monitoring of blood flow and nitric oxide (NO) release were measured simultaneously with a laser Doppler flowmeter and an NO-selective electrode, respectively. The NO2–NO3 and malonaldehyde (MDA) concentrations were measured in the experimental urinary bladders. Clamping of the abdominal aorta, blood flow was rapidly decreased and NO release was gradually increased. After removing the clip, blood flow was rapidly increased and NO release was gradually returned to the basal level. These movements of blood flow and NO release were inhibited by treatment with sivelestat sodium hydrate in a dose-dependent manner. Both NO2–NO3 and MDA concentrations in the bladder were increased by induction of IR, and NO2–NO3 and MDA concentrations were decreased by treatment with high dose of sivelestat sodium hydrate significantly. Our data indicated that sivelestat sodium hydrate could inhibit increasing NO2–NO3 and MDA concentrations by IR, and it has potentiality protective effects on IR injury in the rat urinary bladder.


  • Beneficial effect of preconditioning on ischemia–reperfusion injury in the rat bladder in vivo

    by Yoshie Hisadome, Motoaki Saito, Tomoharu Kono, Itaru Satoh, Yukako Kinoshita, Keisuke Satoh


  • Ability of Cyclohexenonic Long-Chain Fatty Alcohol to Reverse Diabetes-Induced Cystopathy in the Rat

    by Motoaki Saito, Yukako Kinoshita, Itaru Satoh, Chiko Shinbori, Hiroto Suzuki, Masashi Yamada, Takeshi Watanabe, Keisuke Satoh


  • N-hexacosanol ameliorates streptozotocin-induced diabetic rat nephropathy

    by Motoaki Saito, Yukako Kinoshita, Itaru Satoh, Chiko Shinbori, Tomoharu Kono, Takuya Hanada, Jiro Uemasu, Hiroto Suzuki, Masashi Yamada, Keisuke Satoh


  • Real-time monitoring of nitric oxide and blood flow during ischemia-reperfusion in the rat testis

    by Tomoharu Kono, Motoaki Saito, Yukako Kinoshita, Itaru Satoh, Chiko Shinbori, Keisuke Satoh

    In the present study, we attempted to clarify the role of nitric oxide (NO) and its release during the ischemia-reperfusion rat testis. Eight-week-old male Sprague-Dawley rats were divided into seven groups: age-matched control rats, ischemia (30 minutes)-reperfusion (30 minutes) rats without NG-nitro-L-arginine methyl ester (L-NAME) and L-arginine (L-Arg) treatment, ischemia (30 minutes)-reperfusion (30 minutes) rats treated with L-NAME (10, 30, and 100 mg/kg), ischemia-reperfusion rats treated with L-Arg (10 and 30 mg/kg). Sixty minutes prior to induction of ischemia, L-NAME or L-Arg was administrated intraperitoneally. Real-time monitoring of blood flow and NO release were measured simultaneously with a laser Doppler flowmeter and an NO-selective electrode, respectively. NO2-NO3 and malonaldehyde (MDA) concentrations were measured in the experimental testes. Furthermore, we investigated possible morphological changes in the testis. Clamping of the testicular artery decreased blood flow to 5–20% of the basal level measured before clamping. Immediately following clipping of the artery, NO release rapidly increased. After removing the clip, NO release gradually returned to the basal level. This phenomenon was enhanced by treatment with L-Arg and inhibited by treatment with L-NAME. NO2-NO3 concentrations were increased by treatment with L-Arg and decreased by treatment with L-NAME, while MDA concentrations were increased by treatment with L-NAME and were decreased by treatment with L-Arg. In histological studies, the ischemia-reperfusion caused infiltration of leukocytes and a rupture of microvessels in the testis. Our data suggest that NO has cytoprotective effects on ischemia-reperfusion injury in the rat testis.


  • Preventive effects of cyclohexenonic long-chain fatty alcohol on diabetic cystopathy in the rat

    by Hiroto Suzuki, Motoaki Saito, Yukako Kinoshita, Itaru Satoh, Tomoharu Kono, Chiko ShinBori, Sylakos Anastasios, Masashi Yamada, Keisuke Satoh

    In this study, we investigated the preventive effect of n-hexacosanol on diabetes-induced bladder dysfunction in the rat. Diabetes was induced in 8-week-old male Sprague–Dawley rats by administering an injection of streptozotocin (50 mg/kg, i.p.). The rats were randomly divided into 4 groups (age-matched control rats, diabetic rats without treatment with n-hexacosanol, and diabetic rats treated with n-hexacosanol (2 and 8 mg/kg, i.p. every day)) and maintained for 4 weeks. The serum glucose and serum insulin levels were determined, and the functions of bladder were estimated by voiding behavior, cystometric, and functional studies to carbachol and KCl. Furthermore, we examined possible diabetic induced histological changes in these rats. Treatment with n-hexacosanol did not alter diabetic status including body mass, bladder mass, and serum glucose and serum insulin levels, but significantly improved the maximum contraction pressure of the detrusor and residual urine volume in cystometric studies and Emax values to carbachol in functional studies in a dose-dependent manner. Diabetes induced bladder smooth muscle hypertrophy, which tended to be ameliorated by treatment with n-hexacosanol in a dose-dependent manner. Treatment with n-hexacosanol did not alter the diabetic status, but significantly improved diabetic cystopathy in a dose-dependent manner.


  • Effectiveness of an anti‐inflammatory drug, loxoprofen, for patients with nocturia

    by Motoaki Saito, Masahito Kawatani, Yukako Kinoshita, Keisuke Satoh, Ikuo Miyagawa

    Aim: There is increasing evidence that non‐steroidal anti‐inflammatory drugs are effective for the treatment of nocturia. In this study, we attempted to investigate the role of loxoprofen sodium (loxoprofen) in the therapeutic management of patients with nocturia. Methods: Fifteen benign protastatic hyperplasia and/or overactive bladder patients (13 males and 2 females, 71.1 ± 1.5 years old) with three or more voids per night were involved. These patients had received standard drug therapy. Although these patients had received standard drug therapy for more than half a year, they had still three or more episodes of nocturia. The patients took a single dose of 60 mg of loxoprofen at night prior to sleep. Before and 1 week after the initiation of this therapy, the effects of this treatment were assessed by frequency volume chart and a questionnaire. Results: In the questionnaire, seven patients answered as excellent, six patients demonstrated improvement of their symptoms, two patients did not show a significant change in their symptoms and no patients demonstrated a deterioration in the symptoms. In frequency volume chart, total void per day, total void per night, total urine volume per day, total night urine volume per day and single voided volume in the night before and after this treatment were 9.97 ± 0.81 and 8.99 ± 0.74 per day, 3.82 ± 0.25 and 1.82 ± 0.27 per night, 1349 ± 81 and 1258 ± 91 mL per day, 567 ± 46 and 325 ± 51 mL per night, and 143 ± 13 and 149 ± 10 mL, respectively. Conclusions: Loxoprofen can be effective and useful for patients with nocturia. Our data suggest that the main mechanism of this effect is to decrease urine production during a night's sleep.